Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cP12 · 1 trial · 1 indication
Clinical safety labs will be collected
| Arm | Type | Description |
|---|---|---|
| Open-label | EXPERIMENTAL | Six adult male or female subjects will receive a single administration of 0.01mg/kg of cP12. |
| Name | Type | Description |
|---|---|---|
| cP12 | DRUG | cP12 is a novel fibronectin derived, 14-mer peptide |
Inclusion Criteria: * BMI between 18 kg/m2 (inclusive) and body weight \>/=50kg * TBSA thermal burns up to and including 10%. The selected burn must be superficial (epidermal), superficial partial-thickness, or deep partial-thickness * Able to be infused with cP12 within 2 to 24 hours post burn * A...
cP12 is an investigational small molecule being developed for the treatment of thermal burns. It is currently in Phase 2 clinical development and is not yet approved by the FDA.
cP12 is being developed by United Therapeutics Corporation, a company traded on the NASDAQ under the ticker symbol UTHR.
cP12 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 trial is currently recruiting participants in the United States.
cP12 is being studied in a Phase 2 clinical trial with the identifier NCT06814717. This trial is titled 'A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns' and is currently recruiting participants.
No, the Phase 2 clinical trial of cP12 is not randomized and does not use a control group. It is an uncontrolled study that is also not double-blinded. The trial is designed to assess safety, tolerability, and pharmacokinetics.